← brief for 2026-08-10 · Slowing decline

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Trial No results yet Not peer reviewed

Key takeaways

This trial tests empagliflozin, a kidney-protecting diabetes drug, in children aged 2 to 17 with chronic kidney disease. Kids are randomly given the drug or a placebo (dummy pill) to see if it helps and is safe for them. It is just starting, so there are no results yet.

Who did this work

Run by Boehringer Ingelheim.
Sites: University of Alabama at Birmingham · Phoenix Children's Hospital · University of California Los Angeles · Stanford University School of Medicine · University of California Davis · University of California San Francisco

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-07
https://clinicaltrials.gov/study/NCT07107945